Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors
European Journal of Histochemistry · 2023
DOI: 10.4081/ejh.2023.3688 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Histochemistry, 2023. Verfasst von Kazuhiko Hashimoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Kushimoto Municipality Hospital, Wakayama; Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Saya…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Desmoid Tumors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The details of immune molecules' expression in desmoid tumors (DTs) remain unclear. This study aimed to determine the expression status of the programmed death-1/programmed death ligand 1 (PD1/PD-L1) immune checkpoint mechanism in DTs. The study included patients with DTs (n=9) treated at our institution between April 2006 and December 2012. Immunostaining for CD4, CD8, PD-1, PD-L1, interleukin-2 (IL-2), and interferon-gamma (IFN-γ) was performed on pathological specimens harvested during the biopsy. The positivity rate of each immune component was calculated as the number of positive cells/total cells. The positivity rate was quantified and correlations between the positivity rates of each immune molecule were also investigated. Immune molecules other than PD-1 were stained in tumor cells and intra-tumor infiltrating lymphocytes. The mean ± SD expression rates of β-catenin, CD4, CD8, PD-1, PD-L1, IL-2, and IFN-ɤ were 43.9±18.9, 14.6±6.80, 0.75±4.70, 0±0, 5.1±6.73, 8.75±6.38, and 7.03±12.1, respectively. The correlation between β-catenin and CD4 was positively moderate (r=0.49); β-catenin and PD-L1, positively weak (r=0.25); CD4 and PD-L1, positively medium (r=0.36); CD8 and IL-2, positively medium (r=0.38); CD8 and IFN-ɤ, positively weak (r=0.28); and IL-2 and IFN-ɤ, positively medium (r=0.36). Our findings suggest that PD-L1-centered immune checkpoint mechanisms may be involved in the tumor microenvironment of DTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Kushimoto Municipality Hospital, Wakayama; Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. hazzhiko@med.kindai.ac.jp.
- Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. shunnisi@med.kindai.ac.jp.
- Department of Orthopedic Surgery, Kushimoto Municipality Hospital, Wakayama; Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. shinyashiki@med.kindai.ac.jp.
- Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. tomo0251118zooo@gmail.com.
- Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. rkakinoki@med.kindai.ac.jp.
- Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka. makagi@med.kindai.ac.jp.
Zitieren
APA
Hashimoto, K., Nishimura, S., Shinyashiki, Y., Ito, T., Kakinoki, R., & Akagi, M. (2023). Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors. European Journal of Histochemistry. https://doi.org/10.4081/ejh.2023.3688
Vancouver
Hashimoto K, Nishimura S, Shinyashiki Y, Ito T, Kakinoki R, Akagi M. Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors. European Journal of Histochemistry. 2023. doi:10.4081/ejh.2023.3688
BibTeX
@article{Hashimoto2023,
author = {Hashimoto, Kazuhiko and Nishimura, Shunji and Shinyashiki, Yu and Ito, Tomohiko and Kakinoki, Ryosuke and Akagi, Masao},
title = {Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors},
journal = {European Journal of Histochemistry},
year = {2023},
doi = {10.4081/ejh.2023.3688}
}
EUVIMED